Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data
Allergy Oct 27, 2017
Staubach P, et al. - In the X-ACT study, quality of life (QoL) in association with omalizumab treatment was assessed in chronic spontaneous urticaria (CSU) patients with angioedema refractory to high doses of H1-antihistamines. Omalizumab was supported as a treatment option in patients with severe H1-antihistamine-refractory CSU with angioedema.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
